Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.2 EUR | 0.00% | -0.89% | -1.33% |
2023 | PharmaSGP Holding SE Reports Earnings Results for the Nine Months Ended September 30, 2023 | CI |
2023 | Tranche Update on PharmaSGP Holding SE's Equity Buyback Plan announced on January 9, 2023. | CI |
Business Summary
Number of employees: 79
Sales per Business
EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Health Brands
96.1
%
| 61 | 93.3 % | 82 | 96.1 % | +35.26% |
Beauty Brands
3.9
%
| 4 | 6.7 % | 3 | 3.9 % | -23.43% |
Sales per region
EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Germany
71.5
%
| 46 | 70.3 % | 61 | 71.5 % | +33.44% |
Italy
12.3
%
| 9 | 13.1 % | 11 | 12.3 % | +23.15% |
Austria
11.4
%
| 8 | 11.9 % | 10 | 11.4 % | +24.90% |
Other European Countries
4.9
%
| 3 | 4.6 % | 4 | 4.9 % | +39.24% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Natalie Weigand
CEO | Chief Executive Officer | 43 | 31/12/16 |
Michael Rudolf
DFI | Director of Finance/CFO | 50 | 31/12/16 |
Lara Mögenburg
HRO | Human Resources Officer | - | 29/02/20 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Axel Rebien
BRD | Director/Board Member | 52 | 31/05/20 |
Clemens Fischer
CHM | Chairman | 49 | 03/03/20 |
Director/Board Member | 43 | 03/03/20 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 12,000,000 | 2,222,213 ( 18.52 %) | 9,787 ( 0.0816 %) | 18.52 % |
Company contact information
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.33% | 284M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- PSG Stock
- Company PharmaSGP Holding SE